HALO logo
halo search icon
Genmab A/S Sponsored ADR

US$27.21

Price Change Indicator
1.53 (5.96%)
Genmab A/S Sponsored ADR
GMAB · NAS

Genmab A/S Sponsored ADR

Start Trading GMAB for Free

US$27.21

Price Arrow1.53 (5.96%)
20/05/2026 04:00:01 PM
All-ConsensusConsensus Cheap
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Genmab A/S Sponsored ADR Overview

GMAB Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About GMAB

icon
icon

Telephone

45.70.20.27.28

icon

Address

Valby, Carl Jacobsens Vej 30, Copenhagen, Central Denmark 2500

Description

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

GMAB Price Chart

Key Stats

Market Cap

US$16.03B

PE

19.80

EV/EBITDA

17.4

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 20.14 - 35.43

Trade Value (12mth)

US$12,092,686.00

1 week

-3.24%

1 month

-5.1%

YTD

-19.3%

1 year

25.15%

All time high

49.07

Key Fundamentals

EPS 3 yr Growth

31.90%

EBITDA Margin

35.50%

Operating Cashflow

$1,190m

Free Cash Flow Return

14.70%

ROIC

11.90%

Interest Coverage

21.70

Quick Ratio

2.00

Other Data

Shares Outstanding (Fully Diluted)

639m

HALO Sector

Healthcare

Next Company Report Date

24-Feb-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

GMAB Announcements

Latest Announcements

DateAnnouncements
14 May 26
13 May 26
09 May 26
08 May 26
18 April 26

GMAB Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock0.971.771.55locklocklock
EPS (Fully Diluted)
 $locklocklocklock0.961.761.54locklocklock
Growth
 %locklocklocklock-17.983.3-12.3locklocklock
PE
 Xlocklocklocklock32.911.819.8locklocklock
EV/EBITDA
 Xlocklocklocklock20.71017.4locklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Genmab A/S Sponsored ADR (GMAB:NAS)?
Halo FAQ
The current share price of Genmab A/S Sponsored ADR (GMAB:NAS) is USD$27.21.
What is the 52-week high share price for Genmab A/S Sponsored ADR (GMAB:NAS)?
Halo FAQ
The 52-week high share price for Genmab A/S Sponsored ADR (GMAB:NAS) is USD$35.43.
What is the 52-week low share price for Genmab A/S Sponsored ADR (GMAB:NAS)?
Halo FAQ
The 52-week low share price for Genmab A/S Sponsored ADR (GMAB:NAS) is USD$20.14.
What is the dividend yield for Genmab A/S Sponsored ADR (GMAB:NAS)?
Halo FAQ
Genmab A/S Sponsored ADR (GMAB:NAS) does not pay a dividend.
What was Genmab A/S Sponsored ADR (GMAB:NAS) last dividend payment?
Halo FAQ
Genmab A/S Sponsored ADR (GMAB:NAS) does not pay a dividend.
What is the franking level for Genmab A/S Sponsored ADR (GMAB:NAS)?
Halo FAQ
Genmab A/S Sponsored ADR (GMAB:NAS) has a franking level of 0.00%.
In which sector is Genmab A/S Sponsored ADR (GMAB:NAS) classified?
Halo FAQ
Genmab A/S Sponsored ADR (GMAB:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for Genmab A/S Sponsored ADR (GMAB:NAS)?
Halo FAQ
The current P/E ratio for Genmab A/S Sponsored ADR (GMAB:NAS) is 19.80.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial